ClinicalTrials.gg
CompletedNCT04703868Updated Jan 24, 2024

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

A Phase 1 interventional study of Rabeprazole Sodium 10mg and Rabeprazole Sodium 20mg in Gastroesophageal Reflux Disease, sponsored by Yungjin Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Yungjin Pharm. Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
21st of 39
88 · median 100
Started
2021
the only one that year
Phase 1
7 of 40
none open now
Registered
40th of 40
by date

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 1, and was the 40th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Read the detailed description

This study is to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

03

Conditions studied

  • Gastroesophageal Reflux Disease
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19\~55 years in healthy volunteers
  • is more than 18.0 kg/m\^2 , no more than 28.0 kg/m\^2
  • Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of in writing

Exclusion criteria

Exclusion Criteria:

  • Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
  • Subjects who were judged ineligible by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    YPI-011 10/500mg

    Part A: 1 tablet administered before the breakfast during 7 days

    Drug: Rabeprazole Sodium 10mg

  • Experimental
    YPI-011 20/500mg

    Part B: 1 tablet administered before the breakfast during 7 days

    Drug: Rabeprazole Sodium 20mg

Interventions

  • Part A: 1 tablet administered before the breakfast during 7 days

    Also known as: Reference drug

  • Part B: 1 tablet administered before the breakfast during 7 days

    Also known as: Reference drug

06

What researchers measure

Primary outcomes

  1. Integrated gastric acidity

    Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 7th dose

    Time frame: From Day 1 up to Day 28

  2. AUCt,ss

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

Secondary outcomes

  1. Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 1 st dose

    Evaluateion PD Rabeprazole after multiple dose

    Time frame: 24 hours

  2. Percent of time with gastric pH>4 for 24 hour interval after 1st and 7th dose

    Evaluateion PD Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 28

  3. Mean and median gastric pH after 1st and 7th dose

    Evaluateion PD Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 28

  4. AUCτ

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  5. Cmax

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  6. Tmax

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  7. t1/2

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  8. CL/F

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  9. Vz/F

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  10. Cmin,ss,

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  11. Cmax,ss

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  12. Cav,ss,

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  13. Tmax,ss

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  14. t1/2,ss

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  15. CLss/F

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

  16. Vss/F

    Evaluateion PK Rabeprazole after multiple dose

    Time frame: From Day 1 up to Day 29

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Daehak-ro Jongno-gu 110-744, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2021, 4 months.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 4 months is close to that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Jan 13, 2021
Primary completionActual
Jun 1, 2021
CompletionActual
Jun 14, 2021
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04703868
Lead sponsor
Yungjin Pharm. Co., Ltd.
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Jan 13, 2021
Primary completion
Jun 1, 2021
Completion
Jun 14, 2021
Last update
Jan 24, 2024

Study contacts

Seunghwan Lee, M.D., Ph.D
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion